AIRNA
AiRNA
AIRNA is a biotechnology company developing RNA-editing therapeutics through its RESTORE+™ platform, founded with support from ARCH Venture Partners and based on the academic research of co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University) . Its lead clinical candidate targets Alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting the lungs and liver . In August 2024, AIRNA closed a $90 million Series A led by Forbion, with participation from new investors including Ono Venture Investment and Alexandria Venture Investments, as well as existing backers ARCH Venture Partners and ND Capital; Gaorong Capital also joined the round . The company aims to advance its first candidate into clinical trials and expand its pipeline of precision RNA-editing drugs optimized for sequence, chemistry, and delivery .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange listing!
METiS Pharmaceuticals, the world's first publicly listed AI-driven drug delivery company, goes public, ushering in a new era for biopharmaceuticals.
Heart Capital Congratulates METiS Pharmaceuticals on Successful Listing on the Main Board of the Hong Kong Stock Exchange | Heart Star PORTFOLIO
The world's first publicly listed AI drug delivery company.
Code Moment | Congratulations to METiS Pharmaceuticals on Its HKEX Listing, the World's First AI Drug Delivery Stock
Source Code Capital participated in METiS Pharmaceuticals' angel round in 2020 and continued to increase its stake in subsequent rounds.
AIRNA Closes $90 Million Series A to Advance Novel RNA-Editing Therapeutics
Accelerate the advancement of best-in-class drug candidates into clinical trials.
MaKe | MaHui Member METiS Pharmaceuticals Closes $100 Million Series C, Leading the "AI + Drug Delivery" Track
5Y News | 5Y Capital Portfolio Company METiS Pharmaceuticals Closes $100 Million Series C Round
Focused on "AI-powered drug delivery."
